Advertisement

Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma

  • J.-W. Feng
  • X.-H. Yang
  • B.-Q. Wu
  • D.-L. Sun
  • Y. JiangEmail author
  • Z. QuEmail author
Research Article
  • 19 Downloads

Abstract

Background

Central lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC) is common. But the association between primary tumor characteristics and specific features of metastatic lymph nodes in PTC has not been fully identified. Determining risk factors for LNM may help surgeons determine rational extent of lymph node dissection.

Methods

Data from 432 patients who underwent thyroidectomy with cervical lymph node dissection for PTC were retrospectively analyzed. The relationships between LNM to central compartment or lateral compartment and clinicopathologic factors were analyzed. Cox regression model was used to determine the risk factors for recurrence-free survival (RFS).

Results

Central lymph node metastasis (CLNM) and lateral lymph node metastasis (LLNM) were found in 216 (50.0%) and 65 (15.0%) patients, respectively. In the multivariate analysis for CLNM, patients < 45 years of age (OR 2.037, 95% CI 1.388–2.988, P < 0.001), extrathyroidal invasion (OR: 2.144, 95% CI 0.824–5.457, P = 0.011), vascular invasion (OR 13.817, 95% CI 1.694–112.693, P = 0.014), LLNM (OR 2.851, 95% CI 1.196–6.797, P = 0.014) and TNM Stage III–IV (OR 465.307, 95% CI 113.903–1900.826, P < 0.001) were independent predictors for high prevalence of CLNM. In the multivariate analysis for LLNM, tumor size more than 1cm (OR 3.474, 95% CI 1.728–6.985, P < 0.001) and CLNM (OR 5.532, 95% CI 2.679–11.425, P < 0.001) were independent predictors for high prevalence of LLNM. Moreover, tumor with T3–T4 stage, extrathyroidal invasion and CLNM were the significant factors related to the RFS.

Conclusion

For patients with pre-operative risk factors of LNM, an accurate preoperative evaluation of central compartment or lateral compartment is needed to find suspicious lymph nodes. And prophylactic lymph node dissection should be performed in patients with high risk of CLNM. Moreover, we suggest performing close follow-up for patients with high risk of RFS.

Keywords

Papillary thyroid carcinoma Lymph node metastases Extrathyroidal invasion Vascular invasion Recurrence Recurrence-free survival 

Notes

Acknowledgements

Bao-Qiang Wu took charge of conceiving and designing the study; Xing-Hai Yang were responsible for collecting the data and analyzing and interpreting the data; Jia-Wei Feng took charge of writing the manuscript; Dong-Lin Sun was responsible for providing critical revisions; approving the final version of the manuscript was in charge of Yong Jiang and Zhen Qu. Lei Qin, the english language editor, was responsible for correcting language and grammar issues.

Compliance with ethical standards

Conflict of interest

This manuscript has not been published nor submitted for publication elsewhere. All authors have contributed significantly, and agree with the content of the manuscript. The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

Ethical approval

This study has been approved by the Institutional Review Board of Changzhou First People’s Hospital ethics committee, and has been performed according to the ethical standards laid down in the 1964 Declaration of Helsinki.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Lim H, Devesa SS, Sosa JA, et al. rends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–48.CrossRefGoogle Scholar
  2. 2.
    Morris LGT, Sikora AG, Tosteson TD, et al. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013;23(7):885–91.CrossRefGoogle Scholar
  3. 3.
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–28.CrossRefGoogle Scholar
  4. 4.
    Shaha A. Prognostic factors in papillary thyroid carcinoma and implications of large nodal metastasis. Surgery. 2004;135(2):237–9.CrossRefGoogle Scholar
  5. 5.
    Kyu Eun L, Il Yong C, Eunyoung K, et al. Ipsilateral and contralateral central lymph node metastasis in papillary thyroid cancer: patterns and predictive factors of nodal metastasis. Head Neck. 2013;35(5):672–6.CrossRefGoogle Scholar
  6. 6.
    Grogan RH, Kaplan SP, Cao H, et al. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery. 2013;154(6):1436–47.CrossRefGoogle Scholar
  7. 7.
    Beasley NJ, Lee J, Eski S, et al. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg. 2002;128(7):825.CrossRefGoogle Scholar
  8. 8.
    Ito Y, Kudo T, Kobayashi K, et al. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5768 patients with average 10-year follow-up. World J Surg. 2012;36(36):1274–8.CrossRefGoogle Scholar
  9. 9.
    Carty SE, Cooper DS, Doherty GM, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19(11):1153–8.CrossRefGoogle Scholar
  10. 10.
    Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRefGoogle Scholar
  11. 11.
    Tuttle RM, Ball DW, Byrd D, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2010;8(11):1228–744.CrossRefGoogle Scholar
  12. 12.
    Inoue H, Nibu K, Saito M, et al. Quality of life after neck dissection. Arch Otolaryngol Head Neck Surg. 2006;132(132):662–6.CrossRefGoogle Scholar
  13. 13.
    Terrell JE, Welsh DE, Bradford CR, et al. Pain, quality of life, and spinal accessory nerve status after neck dissection. Laryngoscope. 2010;110(4):620–6.CrossRefGoogle Scholar
  14. 14.
    Jr SB, Ferris RL, Goldenberg D, et al. American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid. 2012;22(5):501.CrossRefGoogle Scholar
  15. 15.
    Group ATASW, Carty SE, Cooper DS, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid, 2009, 19(11):1153–1158.CrossRefGoogle Scholar
  16. 16.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6):1471–1474.CrossRefGoogle Scholar
  17. 17.
    Parameswaran R, Sohail A, Ezzat TM, et al. The number of positive lymph nodes in the central compartment has prognostic impact in papillary thyroid cancer. Langenbecks Arch Surg. 2013;398(3):377–82.CrossRefGoogle Scholar
  18. 18.
    Ji JM, Jong Ho Y, Ji Min H, et al. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur J Endocrinol. 2013;168(2):219–25.CrossRefGoogle Scholar
  19. 19.
    Wang LY, Palmer FL, Nixon IJ, et al. Central lymph node characteristics predictive of outcome in patients with differentiated thyroid cancer. Thyroid. 2014;24(12):1790–5.CrossRefGoogle Scholar
  20. 20.
    Noguchi S, Noguchi A, Murakami N Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer,2015,26(5):1053-1060.CrossRefGoogle Scholar
  21. 21.
    Takami H, Ito Y, Okamoto T, et al. Therapeutic strategy for differentiated thyroid carcinoma in japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg. 2011;35(1):111–21.CrossRefGoogle Scholar
  22. 22.
    Yuan J, Gang Z, Du J, et al. To identify predictors of central lymph node metastasis in patients with clinically node-negative conventional papillary thyroid carcinoma. Int J Endocrinol. 2016;2016:1–6.CrossRefGoogle Scholar
  23. 23.
    Koo BS, Choi EC, Yoon YH, et al. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. Ann Surg. 2009;249(5):840–4.CrossRefGoogle Scholar
  24. 24.
    Kim H, Kim J-A, Son EJ, et al. Preoperative prediction of the extrathyroidal extension of papillary thyroid carcinoma with ultrasonography versus MRI: a retrospective cohort study. Int J Surg. 2014;12(5):544–8.CrossRefGoogle Scholar
  25. 25.
    Kim E, Park JS, Son KR, et al. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid. 2008;18(4):411.CrossRefGoogle Scholar
  26. 26.
    Guidoccio F, Grosso M, Orsini F, et al. Thyroid ultrasound and other imaging procedures in the pediatric age. Curr Pediatr Rev. 2016;12(4):253–64.CrossRefGoogle Scholar
  27. 27.
    Nobuyuki W, Quan-Yang D, Kiminori S, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237(3):399–407.Google Scholar
  28. 28.
    Mirallié E, Visset J, Sagan C, et al. Localization of cervical node metastasis of papillary thyroid carcinomaa. World J Surg. 1999;23(9):970–4.CrossRefGoogle Scholar
  29. 29.
    Arora N, Turbendian HK, Scognamiglio T, et al. Extrathyroidal extension is not all equal: implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery. 2008;144(6):942–8.CrossRefGoogle Scholar
  30. 30.
    Clain JB, Sophie S, Laura DR, et al. Extrathyroidal extension predicts extranodal extension in patients with positive lymph nodes: an important association that may affect clinical management. Thyroid. 2014;24(6):951–7.CrossRefGoogle Scholar
  31. 31.
    Noguchi S, Yamashita H, Uchino S, et al. Papillary microcarcinoma. World J Surg. 2008;32(5):747–53.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  1. 1.The Third Affiliated Hospital of Soochow UniversityChangzhou First People’S HospitalChangzhouChina

Personalised recommendations